Australian pharma patentees now face an uphill battle to obtain interlocutory injunctions

The tide has turned against rights holders in recent years, write Gavin Adkins and Jacqueline Simpkin of Griffith Hack – though an accompanying trend of expedited trials offers some consolation

Get unlimited access to all IAM content